BioPharma
Key Steps For Biopharma Startups Getting Ready For EU HTA
What is the Joint European HTA?
Navigating pricing and reimbursement in the European Union (EU) can be a complex task for emerging biopharmaceutical companies (EBPs), defined as those with less than $200 million in estimated annual R&D spending or global...
BioPharma
Elevating Biopharmaceutical Projects With The Right CDMO
In the biopharma industry, selecting the right contract development and manufacturing organization (CDMO) is pivotal to a successful pharmaceutical development journey. This decision hinges on two critical factors: a customer-centric approach and team cohesion. In this blog, we explore...
BioPharma
Overcoming Challenges In Biopharma Novel Drug Manufacturing
The biopharmaceutical sector is undergoing a significant transformation in treating complex diseases, especially in oncology, driven by innovative drug approaches. This shift entails personalized therapies, combination treatments, and novel go-to-market strategies to address specific patient groups. As the industry...
BioPharma
Enhanced Biopharmaceutical Release: Autonomous PAT Power
Speeding up biomanufacturing using automated Process Analytical Technology (PAT) systems
A2P2 and Micro Sequential Injection (SI), two cutting-edge process analysers, have been cited as autonomous PAT platform that enables quick testing and release of biopharmaceutical products.
An insight has showcased two...
BioPharma
Overcoming Treatment Challenges With Cell And Gene Therapies
Gene and cell therapies have the potential to revolutionize healthcare by reprogramming the immune system to treat diseases that are difficult to address with traditional medicine. These therapies involve introducing, replacing, or deactivating genes in cells, either inside or...
BioPharma
Boosting Innovation And Value In UK Biopharma And Medtech
New recommendations from Imperial College London aim to boost competitiveness in the UK's biopharma and Medtech sectors. It assesses the value-added per capita in these sectors and provides insights into their needs, challenges, and opportunities. Technological solutions and policy...
BioPharma
Cell And Gene Therapy CDMO Services Market Is On The Rise
The global cell and gene therapy Contract Development and Manufacturing Organization (CDMO) services market, which was valued at USD 5,193.7 million in 2022, is expected to grow at a CAGR of 17.5% during the forecast period from 2023 to...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read